20n Bio

Founded in 2021 and based in the US, 20n Bio, Limited. , trading as 20n Bio, specializes in the discovery and development of cyclic peptides. The company was led by its founder and CEO Mingfu Zhu. It has a Chinese branch in Hangzhou under the name Hangzhou Tengdi Biomedical Technology Co.

, Ltd. In May 2026, 20n Bio raised USD 750 million in seed+ funding. 20n Bio specializes in the discovery and development of cyclic peptides for therapeutic use, leveraging a proprietary high-throughput screening platform that can evaluate trillions of peptides simultaneously. This technology facilitates the identification of high-affinity peptides with optimal therapeutic properties, which can be utilized in various modalities such as oral peptides, radioligand therapy, and peptide-drug conjugates.

The company generates revenue through strategic partnerships and licensing agreements with pharmaceutical and biotechnology firms, facilitating the development and commercialization of novel peptide therapeutics. Transactions typically occur through B2B agreements where clients license early peptide candidates that emerge from 20n Bio's high-throughput discovery platform. The company will use the seed+ funding to further strengthen its high-throughput cyclic peptide discovery platform, promote the full integration of AI technology into the cyclic peptide discovery and optimization process, and advance its proprietary innovative drug pipeline. It will also advance its internal pipeline development, focusing on areas with clear clinical evidence and well-defined translational pathways, to accelerate the discovery and translation of next-generation cyclic peptide drugs.